Back to HBOT Services

COVID-19 creates significant inflammation in lung tissue, preventing oxygen from reaching the bloodstream and resulting in organ hypoxia. In severe cases, this can lead to organ failure. Mechanical ventilation forces air into the lungs but is not particularly effective at forcing oxygen into the bloodstream—and forced ventilation causes further stress to already damaged lung tissue.

The increased pressure that a hyperbaric oxygen chamber produces oxygenates the fluid of the body directly, without relying on the blood supply. This relieves organ hypoxia much more quickly than ventilation, without stressing lung tissue.

In addition to being a potent virucidal agent, HBOT addresses the inflammation in the lungs themselves—the root cause preventing oxygen from reaching the bloodstream. HBOT also reduces coagulation factors and pro-inflammatory cytokines, effectively addressing the increased clotting and cytokine storm that COVID-19 can create.

Hyperbaric Oxygen Therapy directly addresses the core pathophysiology of severe COVID-19. By delivering 100% oxygen at increased atmospheric pressure, HBOT dramatically increases dissolved oxygen in blood plasma, bypassing damaged lung tissue to oxygenate organs directly.

Dr. Paul Harch and other researchers note that HBOT not only lowers the mortality rate but can avert the need for mechanical ventilation and shorten hospital stays. Clinical trials and case series have demonstrated improved oxygenation, reduced inflammatory markers, and faster recovery times.

HBOT acts as a potent anti-inflammatory, reducing the cytokine storm that drives much of the damage in severe COVID-19. It also helps resolve the micro-clotting that contributes to organ damage and supports tissue repair in the lungs and other affected organs.

Published Research & Clinical Studies